IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering an aggregate of 140,860 shares of its common stock to twenty-seven new, non-executive employees. The awards were granted on June 18, 2026, under the company's Amended and Restated 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.91, which was the closing price on the grant date, and vests over a three-year period.

Iovance Biotherapeutics announced that Australia's Therapeutic Goods Administration (TGA) granted conditional approval for Amtagvi (lifileucel) for previously treated advanced melanoma. This marks the company's third marketing authorization for Amtagvi and represents the first T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy. The approval is significant given Australia's high melanoma rates and was based on positive safety and efficacy data from the C-144-01 clinical trial.

Iovance Biotherapeutics received U.S. FDA allowance for its Investigational New Drug (IND) application for IOV-5001, a next-generation interleukin-12 (IL-12) tethered TIL therapy. The company plans to initiate a Phase 1/2 basket trial in the second half of 2026, targeting advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, as well as other highly prevalent solid tumors responsible for over 100,000 U.S. deaths annually. IOV-5001 is engineered to enhance efficacy in immunologically 'cold' tumors and improve safety by localizing IL-12 activity within the tumor, building on prior therapy that showed a 63% objective response rate.

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for an aggregate of 93,340 shares of its common stock to thirteen new, non-executive employees on May 21, 2026. These awards were issued under the company's Amended and Restated 2021 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $3.70, matching the closing price on the grant date, and vests over a three-year period, subject to continued employment.

Iovance Biotherapeutics, Inc. announced that its Interim CEO, President and General Counsel, Fred Vogt, and Chief Financial Officer, Corleen Roche, will participate in a fireside chat. The event is part of the 2026 Jefferies Global Healthcare Conference, scheduled for June 4, 2026, at 1:25 p.m. ET in New York, NY. A webcast of the presentation will be available on the company's investor relations website.

Iovance Biotherapeutics reported strong first quarter 2026 financial results, with total product revenue reaching approximately $71 million, a 45% increase year-over-year. The company provided optimistic guidance, projecting Q2 2026 total product revenue between $86 million and $88 million, and full-year 2026 revenue of $350 million to $370 million. Additionally, Iovance highlighted positive initial data from its IOV-END-201 trial in metastatic serous endometrial cancer, showing a 40% confirmed objective response rate, and announced progress across its pipeline and global commercial expansion for Amtagvi.

Iovance Biotherapeutics reported a significant increase in product revenue for Q1 2026, reaching $71.4 million, up from $49.3 million in Q1 2025. The company also substantially reduced its net loss to $(79.0) million, compared to $(116.2) million in the prior year. Iovance continues to commercialize Amtagvi® and Proleukin®, with Amtagvi® approvals in the U.S. and Canada, and plans for further global expansion despite withdrawing initial marketing applications in the EU and UK for resubmission. The company maintains a strong liquidity position with $319.4 million in cash and investments, sufficient to fund operations for at least the next twelve months.

Iovance Biotherapeutics reported first quarter 2026 total revenue of ~$71 million, marking a ~45% year-over-year increase, with U.S. Amtagvi revenue at ~$60 million. The company provided strong guidance, expecting 2Q26 revenue between $86 million and $88 million, and full-year 2026 revenue of $350 million to $370 million. Additionally, Iovance announced positive initial data for lifileucel in metastatic serous endometrial cancer, showing a 40% confirmed objective response rate. The company is accelerating Amtagvi adoption and commercial expansion, advancing multiple clinical trials, and reported a 12% decrease in R&D expenses compared to 4Q25. Dr. Friedrich Graf Finckenstein, Chief Medical Officer, will retire in June 2026.

Iovance Biotherapeutics, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on Wednesday, June 10, 2026. Key proposals include the election of six directors, advisory votes on executive compensation and its frequency, and the ratification of Ernst & Young LLP as the independent auditor. The company also seeks approval to amend its 2020 Employee Stock Purchase Plan to increase authorized shares by 1,000,000 and to increase the total authorized common stock from 500,000,000 to 650,000,000 shares. Additionally, director Wendy Yarno will retire from the Board and will not stand for re-election.

Iovance Biotherapeutics, Inc. announced it will host a conference call and live audio webcast on Thursday, May 7, 2026, at 8:30 a.m. ET. The call is scheduled to report the company's first quarter 2026 financial results and provide corporate updates. Interested parties can register for the webcast or access it through the Investors section of the company's website.